<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05381090</url>
  </required_header>
  <id_info>
    <org_study_id>288862</org_study_id>
    <nct_id>NCT05381090</nct_id>
  </id_info>
  <brief_title>Circulating Ghrelin as a Biomarker for Dementia</brief_title>
  <acronym>GDEM3</acronym>
  <official_title>Circulating Ghrelin as a Biomarker for Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swansea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swansea University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and&#xD;
      unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive&#xD;
      impairment. It will focus on validating pilot data generated following the analysis of&#xD;
      Parkinson's disease (PD), Parkinson's disease dementia (PDD) and healthy cohorts (IRAS&#xD;
      project ID: 250933). In addition to the advantages of study replication we will extend the&#xD;
      analysis to include two further patient groups that are associated with cognitive&#xD;
      impairments, namely, Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). This&#xD;
      study will increase confidence in the replication of our findings.&#xD;
&#xD;
      This will be a cross-sectional study using peripheral venous blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2022</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ghrelin ratio in PD and PDD</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Quantification of circulating ghrelin peptides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ghrelin ratio in AD and DLB</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Quantification of circulating ghrelin peptides</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venous blood collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venous blood collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's disease dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venous blood collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venous blood collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venous blood collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Venous blood collection</intervention_name>
    <description>Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <arm_group_label>Parkinson's disease dementia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 60 years&#xD;
&#xD;
          -  Subject or carer / legal representative is willing to sign consent document&#xD;
&#xD;
        Specific criteria for each group;&#xD;
&#xD;
        Parkinson's Disease&#xD;
&#xD;
          -  PD diagnosed by a movement disorder specialist and meets the diagnosis of PD&#xD;
&#xD;
          -  MoCA &gt; 26/30&#xD;
&#xD;
          -  No evidence of cognitive symptoms causing functional impairment&#xD;
&#xD;
        Parkinson's Disease Dementia&#xD;
&#xD;
          -  PD diagnosed by a movement disorder specialist&#xD;
&#xD;
          -  Duration of motor symptoms &gt; 1 year&#xD;
&#xD;
          -  Meets MDS task force criteria for PDD&#xD;
&#xD;
          -  MoCA &lt; 21/30&#xD;
&#xD;
        Dementia with Lewy Bodies&#xD;
&#xD;
          -  Meets criteria for probable DLB as defined by the 4th report of the DLB consortium&#xD;
&#xD;
        Alzheimer's Disease&#xD;
&#xD;
          -  Meets criteria for probable AD dementia (consistent with NIA/AA core clinical criteria&#xD;
             for probable AD dementia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 60 years&#xD;
&#xD;
          -  Current major depression&#xD;
&#xD;
          -  Use of anti-psychotic medication&#xD;
&#xD;
          -  Type I or Type II diabetes mellitus (DM) (excluding diet-controlled DM)&#xD;
&#xD;
          -  Tobacco use&#xD;
&#xD;
          -  BMI &lt;15.0 kg/m2&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Comorbid gastrointestinal disease i.e. includes Coeliac, active Inflammatory Bowel&#xD;
             Disease (Colitis), evidence for active gastric ulcers within the last 12 months, but&#xD;
             excludes gastroesophageal reflux and hiatus hernia.&#xD;
&#xD;
          -  &gt;5 kg weight change over the preceding 3 months (determined by researcher from&#xD;
             previous clinic visit and discussion with partner/carer)&#xD;
&#xD;
          -  Significant active comorbidity&#xD;
&#xD;
          -  Difficult venous access&#xD;
&#xD;
          -  Vagotomy&#xD;
&#xD;
        Additional disease specific exclusions;&#xD;
&#xD;
          -  Parkinson's Disease exclusion criteria&#xD;
&#xD;
          -  Evidence of dementia or mild cognitive impairment&#xD;
&#xD;
          -  Deep brain stimulation (DBS)&#xD;
&#xD;
          -  Use of Duodopa&#xD;
&#xD;
        Parkinson's Disease Dementia exclusion criteria&#xD;
&#xD;
          -  Dementia within 12 months of diagnosis of PD&#xD;
&#xD;
          -  DBS&#xD;
&#xD;
        Dementia with Lewy bodies exclusion criteria&#xD;
&#xD;
          -  Onset of motor Parkinsonism symptoms greater than 12 months prior to dementia&#xD;
             diagnosis&#xD;
&#xD;
        Alzheimer's dementia exclusion criteria&#xD;
&#xD;
          -  Presence of PD, PDD, DLB, or Frontotemporal Dementia (FTD)&#xD;
&#xD;
        Controls exclusion criteria&#xD;
&#xD;
          -  Evidence of parkinsonism&#xD;
&#xD;
          -  Evidence of dementia or mild cognitive impairment&#xD;
&#xD;
          -  MoCA &lt;26/30&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey S Davies, BSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swansea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola A Griffiths</last_name>
    <phone>0179260</phone>
    <phone_ext>3849</phone_ext>
    <email>resgov@swansea.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathie Wareham</last_name>
    <email>kathie.wareham@wales.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swansea University</name>
      <address>
        <city>Swansea</city>
        <zip>sa2 8pp</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathie Wareham</last_name>
      <email>kathie.wareham@wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2022</study_first_posted>
  <last_update_submitted>September 8, 2022</last_update_submitted>
  <last_update_submitted_qc>September 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

